Patients aged 50 years or older with newly diagnosed active giant cell arteritis (GCA) or relapsed GCA within 6 weeks of baseline were recruited. Active disease was defi ned by unequivocal clinical signs and symptoms attributable to GCA (new localised headache, scalp or temporal tenderness, vision loss attributed to ischaemia or otherwise unexplained mouth or jaw pain on mastication or typical polymyalgia rheumatica symptoms combined with imaging or biopsy evidence of vasculitis) with a raised erythrocyte sedimentation rate (ESR) (≥ 30 mm/h) and/or C-reactive protein (CRP) (≥ 1 mg/dL).
The number of relapsed or refractory subjects was capped at 70% of recruits. The authors, appropriately, devised new diagnostic criteria for GCA such that modern imaging data could be included. 2 Concomitant methotrexate was permitted if started more than 6 weeks before enrolment. Notable exclusions were patients who had a history of diverticulitis, a prior episode of major infection or a prior malignancy. Patients had a mean age of 69 years.
The primary aim of the study was to demonstrate superiority of tocilizumab treatment, in terms of the proportion of patients achieving steroid free remission at 52 weeks, against placebo patients who tapered prednisolone over 26 weeks. A key secondary aim was to demonstrate the non-inferiority of tocilizumab versus placebo patients tapering over 52 weeks (non-inferiority margin of -22.5%). Tocilizumab may normalise CRP and ESR 3 without necessarily inducing disease remission thus, to minimise bias, a sensitivity analysis that excluded a need for normal CRP was done on these outcomes. To ensure blinding, all trial personnel were unaware of CRP levels. Effi cacy was assessed by clinicians who managed the prednisolone taper. A laboratory assessor notifi ed effi cacy assessors of ESR values ≥ 30 mm/h, thus risking un-blinding in these patients. Disease fl are was defi ned as a recurrence of clinical features of disease or an ESR ≥ 30 mm/h or the necessity for an increase in prednisolone dose. Remission was defi ned as an absence of fl are and normalisation of CRP (≤ 1 mg/dL). Sustained remission was defi ned as remission from weeks 12 through 52 and adherence to prednisolone taper. Patients who fl ared, or could not adhere to prednisolone taper, switched to open-label prednisolone but continued tocilizumab or placebo as allocated at inception. This study demonstrated that 162 mg of subcutaneous tocilizumab, given weekly or every 2 weeks, when combined with a 26-week prednisolone taper is superior to prednisolone taper alone over 26 or 52 weeks in terms of sustained steroid free remission, disease fl are and cumulative steroid dose (see Table 1 ). Key effi cacy data attained statistical signifi cance (p < 0.001). Adverse effects were comparable though more patients withdrew from tocilizumab due to adverse effects than those on prednisolone alone. Neutropenia, a known adverse effect of tocilizumab, occurred in 4% of tocilizumab patients. Data on osteoporotic fractures were not reported but all enrolled patients were expected to receive calcium and vitamin D but use of bisphosphonates was left to the discretion of the treating physician.
Opinion
GCA, the most common form of vasculitis in older people, responds very well to corticosteroids. Between 51% and 72.5% of patients achieve permanent remission or can discontinue steroids after a median of 21.6 months. 4, 5 In addition, 91% can reduce prednisolone to 5 mg per day after a median of 7.5 months (range 0.2 to 62 months). 5 Despite these impressive responses a substantial proportion of patients experience adverse effects. For example, around 35% of treated patients experience a vertebral or a femoral fracture, 4, 5 bearing in mind that the population prevalence of vertebral fracture in women over 50 years is 14% 6 and that the incidence of vertebral fracture in women over 70 years is around 2% per annum. 7 Clinicians offering steroid-sparing drugs tend to rely on methotrexate or azathioprine. Data for azathioprine are unconvincing but more convincing is the role of methotrexate. 8, 9 A meta-analysis of randomised trials of methotrexate for GCA found that 63% of treated patients experienced a fi rst relapse (including those with non-cranial symptoms) after 48 weeks of treatment compared with 80% of placebo treated patients (hazard ratio for methotrexate 0.65, confi dence interval 0.44 to 0.98). 10 Fractures, a rate of 8%, occurred equally in methotrexate and placebo treated patients. Tumour necrosis factor-α inhibitors have not shown benefi t for polymyalgia rheumatica or GCA but promising data for abatacept, an inhibitor of T cell activation via CTLA-4, using a drug withdrawal design, were published recently. 11 The GiACTA study is a major international effort to fi nd an alternative to steroids to treat this disease. The investigators should be congratulated, particularly as the study tackles key challenges which include diagnosis, defi ning the standard of care in relation to steroid taper, incorporating prednisolone blinding, defi ning endpoints including fl are and remission, and preventing un-blinding where one of the mechanisms of action of the therapy tested is to suppress acute-phase proteins, which are key aspects of assessing disease.
Yet, important challenges remain. Diagnosis can be diffi cult despite new imaging techniques. Assessing disease activity or relapse is particularly challenging when relying on common symptoms such as visual disturbance, headache and shoulder pain in older people. Stone and colleagues excluded patients with a history of diverticulitis, presumably because patients treated with tocilizumab have a higher risk of gastrointestinal perforation, as do those on corticosteroids. 12 In addition, patients with a prior malignancy were excluded. The mean age of included patients was 69 years compared with 75 years in a large observational study. 9 These aspects may limit the generalisability of this study to routine practice. One key concern with the study design is the fact that laboratory assessors reported raised ESR (≥ 30 mm/h) to effi cacy assessors. This event is much more likely to occur in placebo treated patients, due to the effect of tocilizumab on acutephase proteins, 3 thus risking un-blinding and bias towards attribution of clinical features to fl are or active disease in placebo treated patients.
Cessation of steroids in around half of conventionally treated GCA patients may take 2 years. Observations over a longer time should provide greater insight into the benefi ts and risks of tocilizumab. The investigators set a high bar for response to treatment by depending on remission and complete cessation of prednisolone. Clinicians may regard a prednisolone dose below 5 mg daily acceptably safe and suffi ciently good with any steroid sparing therapy. 13 However, the risk of continued prednisolone, even at a low dose, may be substantial in high risk patients.
Should tocilizumab, combined with prednisolone (tapered over 26 weeks), become the standard of care in patients with newly diagnosed GCA? In our opinion, this would be premature. Tocilizumab, a high cost drug, may be better reserved for patients at high risk of corticosteroid complications or those in whom steroid taper during the fi rst few months of therapy is diffi cult because of disease relapse. Certainly, these data are an important step in providing more options for steroidsparing and improving the care of patients with GCA.
